Optimizing the treatment of cytomegalovirus infection in allo-HSCT recipients

References

• Zhang XH, Chen J, Han MZ, et al. The consensus from The Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021 Sep 15;14:145.
   PubMed Web of Science ®Google Scholar
• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016 May 19;127:2427–2438.
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016 Mar;3:e119–27.
   PubMed Web of Science ®Google Scholar
• Meng XY, Fu HX, Zhu XL, et al. Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. Ann Hematol. 2020 Nov;99:2659–2670.
   PubMed Web of Science ®Google Scholar
• Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019 Aug;19:e260–e272.
   Google Scholar
• Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis. 2017 Jan 1;64:87–91.
   PubMed Web of Science ®Google Scholar
• Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019 May;29:e2034.
   PubMed Web of Science ®Google Scholar
• Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021 Dec;19:759–773.
   PubMed Web of Science ®Google Scholar
• Han TT, Xu LP, Liu DH, et al. Cytomegalovirus is a potential risk factor for late-onset hemorrhagic cystitis following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Jan;89:55–61.
   PubMed Web of Science ®Google Scholar
• Forman SJNR, Antin JH, Appelbaum FR. Thomas’ hematopoietic cell transplantation stem cell transplantion. Vol. 2. Wiley & Sons. Ltd.; 2016.
   Google Scholar
• Erbey F, Akçay A, Atay D, et al. Comparison of outcomes after HLA-matched unrelated and αβ T-cell-depleted haploidentical hematopoietic stem cell transplantation for children with high-risk acute leukemia. Pediatr Transplant. 2018 Jun;22(4):e13192.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu LP, Liu KY, et al. Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. J Clin Virol. 2016 Feb;75:10–15.
   PubMed Web of Science ®Google Scholar
• Luo XH, Zhu Y, Chen YT, et al. CMV infection and CMV-specific immune reconstitution following haploidentical stem cell transplantation: an update. Front Immunol. 2021;12:732826.
   PubMed Web of Science ®Google Scholar
• Yan CH, Wang Y, Mo XD, et al. Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020 Jun;55:1147–1160.
   PubMedGoogle Scholar
• Griffiths P. The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination. Antiviral Res. 2020 Apr;176:104732.
   PubMed Web of Science ®Google Scholar
• Sun YQ, Wang Y, Zhang XH, et al. Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation. Ann Hematol. 2019 Aug;98:1877–1883.
   PubMed Web of Science ®Google Scholar
• Zhou JR, Shi DY, Wei R, et al. Co-reactivation of cytomegalovirus and Epstein-Barr virus was associated with poor prognosis after allogeneic stem cell transplantation. Front Immunol. 2020;11:620891.
   PubMed Web of Science ®Google Scholar
• Hakki M, Aitken SL, Danziger-Isakov L, et al. American society for transplantation and cellular therapy series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation. Transplant Cell Ther. 2021 Sep;27 707–719.
   PubMedGoogle Scholar
• Hayden RT, Preiksaitis J, Tong Y, et al. Commutability of the First World Health Organization International Standard for Human Cytomegalovirus. J Clin Microbiol. 2015 Oct;53:3325–3333.
   PubMed Web of Science ®Google Scholar
• Limaye AP, Santo Hayes TK, Huang ML, et al. Quantitation of cytomegalovirus DNA load in dried blood spots correlates well with plasma viral load. J Clin Microbiol. 2013 Jul;51:2360–2364.
   PubMed Web of Science ®Google Scholar
• Sun YQ, Xu LP, Han TT, et al. Detection of human cytomegalovirus (CMV) DNA in feces has limited value in predicting CMV enteritis in patients with intestinal graft-versus-host disease after allogeneic stem cell transplantation. Transpl Infect Dis. 2015 Oct;17:655–661.
   PubMed Web of Science ®Google Scholar
• Mills AM, Guo FP, Copland AP, et al. A comparison of CMV detection in gastrointestinal mucosal biopsies using immunohistochemistry and PCR performed on formalin-fixed, paraffin-embedded tissue. Am J Surg Pathol. 2013 Jul;37:995–1000.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Vij KR, Buller RS, et al. Tissue polymerase chain reaction for the diagnosis of cytomegalovirus disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2017 Feb;92(2):E19–E20.
   PubMed Web of Science ®Google Scholar
• Mavropoulou E, Ternes K, Mechie NC, et al. Cytomegalovirus colitis in inflammatory bowel disease and after haematopoietic stem cell transplantation: diagnostic accuracy, predictors, risk factors and disease outcome. BMJ Open Gastroenterol. 2019;6:e000258.
   PubMed Web of Science ®Google Scholar
• Suarez-Lledo M, Marcos MA, Cuatrecasas M, et al. Quantitative PCR is faster, more objective, and more reliable than immunohistochemistry for the diagnosis of cytomegalovirus gastrointestinal disease in allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2019 Nov;25:2281–2286.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Stevens-Ayers T, Travi G, et al. Cytomegalovirus (CMV) DNA quantitation in bronchoalveolar lavage fluid from hematopoietic stem cell transplant recipients with cmv pneumonia. J Infect Dis. 2017 May 15;215:1514–1522.
   PubMed Web of Science ®Google Scholar
• Lee HY, Rhee CK, Choi JY, et al. Diagnosis of cytomegalovirus pneumonia by quantitative polymerase chain reaction using bronchial washing fluid from patients with hematologic malignancies. Oncotarget. 2017 Jun 13;8:39736–39745.
   PubMedGoogle Scholar
• Iglesias L, Perera MM, Torres-Minana L, et al. CMV viral load in bronchoalveolar lavage for diagnosis of pneumonia in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017 Jun;52:895–897.
   PubMedGoogle Scholar
• Pinana JL, Gimenez E, Gomez MD, et al. Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: implications for the diagnosis of CMV pneumonia. J Infect. 2019 May;78:393–401.
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Abid MB, Auletta JJ, et al. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021 Jun 10;137:3291–3305.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Labopin M, Beelen D, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Blood. 2013 Nov 7;122:3359–3364.
   PubMed Web of Science ®Google Scholar
• Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601–1607.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG, Chemaly RF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015;162:1–10.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017 Dec 21;377:2433–2444.
   PubMed Web of Science ®Google Scholar
• Terao T, Matsuoka KI, Narita K, et al. Letermovir administration to prevent cytomegalovirus reactivation is the potential risk of chronic graft-versus-host disease in patients who received haploidentical stem-cell transplantation with post-transplant cyclophosphamide. Front Oncol. 2021;11:666774.
   PubMed Web of Science ®Google Scholar
• Lorentino F, Xue E, Mastaglio S, et al. Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation. Blood Adv. 2022 May 24;6:3053–3057.
   PubMed Web of Science ®Google Scholar
• Leserer S, Arrieta-Bolanos E, Buttkereit U, et al. Combined analysis of early CD4(+) T cell counts and CMV serostatus may improve cmv risk assessment after allogeneic hematopoietic cell transplantation. Cells. 2021 Nov 26;10:3318.
   PubMed Web of Science ®Google Scholar
• Nesher L, Shah DP, Ariza-Heredia EJ, et al. Utility of the enzyme-linked immunospot interferon-gamma-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients. J Infect Dis. 2016 Jun 1;213:1701–1707.
   PubMed Web of Science ®Google Scholar
• Wagner-Drouet E, Teschner D, Wolschke C, et al. Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica. 2021 Feb 1;106:363–374.
   PubMed Web of Science ®Google Scholar
• Zaghi E, Calvi M, Puccio S, et al. Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT. JCI Insight. 2021 Jun 22;6: 10.1172/jci.insight.146973
   PubMed Web of Science ®Google Scholar
• Yu XX, Shang QN, Liu XF, et al. Donor NKG2C homozygosity contributes to CMV clearance after haploidentical transplantation. JCI Insight. 2022 Feb 8;7: 10.1172/jci.insight.149120
   Web of Science ®Google Scholar
• Westall GP, Cristiano Y, Levvey BJ, et al. A randomized study of quantiferon cmv-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation. Transplantation. 2019 May;103:1005–1013.
   PubMed Web of Science ®Google Scholar
• Anderholm KM, Bierle CJ, Schleiss MR. Cytomegalovirus vaccines: current status and future prospects. Drugs. 2016 Nov;76:1625–1645.
   PubMed Web of Science ®Google Scholar
• Nakamura R, La Rosa C, Longmate J, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol. 2016 Feb;3:e87–98.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Bermudez A, Logan AC, et al. A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. EClinicalMedicine. 2021 Mar;33:100787.
   PubMedGoogle Scholar
• Luo XH, Huang XJ, Liu KY, et al. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010 Jul;16:994–1004.
   PubMed Web of Science ®Google Scholar
• Gottlieb DJ, Clancy LE, Withers B, et al. Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant. Clin Transl Immunology. 2021;10:e1249.
   PubMed Web of Science ®Google Scholar
• Blyth E, Clancy L, Simms R, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013 May 2;121:3745–3758.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Lazzarotto T, Bonifazi F, et al. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: a multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. Clin Transplant. 2019 Oct;33:e13666.
   PubMed Web of Science ®Google Scholar
• Liu KY, Wang Y, Han MZ, et al. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial. Chin Med J (Engl). 2010;123:2199–2205.
   PubMed Web of Science ®Google Scholar
• Navarro D, Amat P, de la Camara R, et al. Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients. Open Forum Infect Dis. 2016 Apr;3:ofw107.
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Chou S, Einsele H, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019 Apr 8;68:1420–1426.
   PubMed Web of Science ®Google Scholar
• Liu J, Kong J, Chang YJ, et al. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality. Clin Microbiol Infect. 2015 Dec;21:1121 e9–15.
   PubMed Web of Science ®Google Scholar
• Shmueli E, Or R, Shapira MY, et al. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis. 2014 Feb 15;209:557–561.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Huang YT, Foldi J, et al. Cytomegalovirus resistance in CD34(+) -selected hematopoietic cell transplant recipients. Transpl Infect Dis. 2018 Jun;20:e12881.
   PubMed Web of Science ®Google Scholar
• Liu J, Chang YJ, Yan CH, et al. Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. J Infect. 2016 Sep;73:261–270.
   PubMed Web of Science ®Google Scholar
• Lodding IP, Jorgensen M, Bennedbaek M, et al. Development and dynamics of cytomegalovirus UL97 ganciclovir resistance mutations in transplant recipients detected by next-generation sequencing. Open Forum Infect Dis. 2021 Oct;8:ofab462.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Bregante S, Tedone E, et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation. 1996 Aug 15;62:376–380.
   PubMed Web of Science ®Google Scholar
• Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 Study. Clin Infect Dis. 2019 Apr 8;68:1255–1264.
   PubMed Web of Science ®Google Scholar
• Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019 Sep 19;381:1136–1147.
   PubMed Web of Science ®Google Scholar
• Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2021 Dec 2;73:101–106.
   PubMedGoogle Scholar
• Phoompoung P, Ferreira VH, Tikkanen J, et al. Letermovir as salvage therapy for cytomegalovirus infection in transplant recipients. Transplantation. 2020 Feb;104:404–409.
   PubMed Web of Science ®Google Scholar
• Kilgore JT, Becken B, Varga MG, et al. Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient. J Pediatric Infect Dis Soc. 2020 Sep 17;9:486–489.
   PubMed Web of Science ®Google Scholar
• Frange P, Leruez-Ville M. Caution is required before recommending wide use of letermovir as salvage therapy for cytomegalovirus diseases. Antimicrob Agents Chemother. 2019 May;63(5).
   Web of Science ®Google Scholar
• Cherrier L, Nasar A, Goodlet KJ, et al. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant. 2018 Dec;18:3060–3064.
   PubMed Web of Science ®Google Scholar
• Knoll BM, Seiter K, Phillips A, et al. Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis. Bone Marrow Transplant. 2019 Jun;54:911–912.
   PubMed Web of Science ®Google Scholar
• El Chaer F, Mori N, Shah D, et al. Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: a case series. Antiviral Res. 2016 Nov;135:91–96.
   PubMed Web of Science ®Google Scholar
• Verkaik NJ, Hoek RA, van Bergeijk H, et al. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature. Transpl Infect Dis. 2013 Dec;15:E243–9.
   PubMed Web of Science ®Google Scholar
• Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis. 2008 May 1;46:1455–1457.
   PubMed Web of Science ®Google Scholar
• Vogel JU, Schmidt S, Schmidt D, et al. The thrombopoietin receptor agonist eltrombopag inhibits human cytomegalovirus replication via iron chelation. Cells. 2019 Dec 20;9: 10.3390/cells9010031
   Web of Science ®Google Scholar
• Mercorelli B, Luganini A, Celegato M, et al. The clinically approved antifungal drug posaconazole inhibits human cytomegalovirus replication. Antimicrob Agents Chemother. 2020 Sep 21; 64;64: 10.1128/AAC.00056-20
   PubMed Web of Science ®Google Scholar
• Tzannou I, Papadopoulou A, Naik S, et al. Off-the-shelf virus-specific t cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017 Nov 1;35:3547–3557.
   PubMed Web of Science ®Google Scholar
• Pei XY, Zhao XY, Chang YJ, et al. Cytomegalovirus-specific t-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus. J Infect Dis. 2017 Nov 15;216:945–956.
   PubMed Web of Science ®Google Scholar
• Pei XY, Liu XF, Zhao XY, et al. Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation. Cell Mol Immunol. 2022 Apr;19:482–491.
   PubMed Web of Science ®Google Scholar
• Pei XY, Zhao XY, Liu XF, et al. Adoptive therapy with cytomegalovirus-specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy. Am J Hematol. 2022 Jun 1;97:762–769.
   PubMed Web of Science ®Google Scholar
• Zhao XY, Pei XY, Chang YJ, et al. First-line therapy with donor-derived human cytomegalovirus (HCMV)-specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation. Clin Infect Dis. 2020 Mar 17;70:1429–1437.
   PubMed Web of Science ®Google Scholar
• Zhao XY, Luo XY, Yu XX, et al. Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation. Br J Haematol. 2017 Jun;177:766–781.
   PubMed Web of Science ®Google Scholar
• Zuo W, Zhao X. Natural killer cells play an important role in virus infection control: antiviral mechanism, subset expansion and clinical application. Clin Immunol. 2021 Jun;227:108727.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003 Jan 15;101:407–414.
   PubMed Web of Science ®Google Scholar
• Zamora D, Duke ER, Xie H, et al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021 Jul 8;138:34–43.
   PubMed Web of Science ®Google Scholar
• Robin C, Thiebaut A, Alain S, et al. Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate program. Biol Blood Marrow Transplant. 2020 May;26(5):978–984.
   PubMed Web of Science ®Google Scholar